References
1. Treatment of age related macular degeneration with photodynamic therapy study group. Photodynamic therapy of subfoveal choroidal neovascularization in age related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials-TAP report. Arch Ophthalmol 1999. 1171329–1345.
2. Kim JW, Kim HK, Kim HC. Photodynamic therapy of choroidal neovascularization in age-related macular degeneration. J Korean Ophthalmol Soc 2002. 431435–1443.
3. Verteporfin roundtable 2000 and 2001 participants: VIP & TAP study group principal investigators. Guidelines for using Verteporfin in photodynamic therapy to treat choroidal neovascularization due to age related macular degeneration and other causes. Retina 2002. 226–18.
4. Treatment of age-related macular degeneration with photodynamic therapy (TAP) study group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin. Two-year results of 2 randomized clinical trials-TAP Report 2. Arch Ophthalmol 2001. 119198–207.
5. Verteporfin in Photodynamic Therapy Study Group (VIP). Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a rando-mized clinical trial including lesions with occult with no classic choroidal neovascularization-verteporfin in photodynamic therapy report 2. Am J Ophthalmol 2001. 131541–560.
6. Treatment of age-related macular degeneration with photodynamic therapy (TAP) study group. Verteporfin (Visudyne) therapy of subfoveal choroidal neovascularization in age-related macular degeneration. Additional information regarding baseline lesion composition's impact on visual outcomes-TAP Report 3. Arch Ophthalmol 2002. 1201443–1454.
7. Rosenfeld PJ. Treatment of age-related macular degeneraiton with photodynamic therapy (TAP) study group. Visual outcomes in patients with minimally classic choroidal neovascularization (CNV): rationale for the Visudyne in minimally classic CNV(VIM) Trial [abstract]. Invest ophthalmol Vis Sci 2001. 42S512.
8. Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, Kim RY. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006. 3551419–1431.
9. Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY, Sy JP, Schneider S. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006. 3551432–1444.
10. Adamis AP, Cunningham ET, Goldbaum M, Guyer DR, Katz B, Patel M. Year 2 efficacy results of 2 randomized controlled clinical trials of pegaptanib for neovascular age-related macular degeneration. Ophthalmology 2006. 1131508.